Capricor Therapeutics (CAPR) Share-based Compensation (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Share-based Compensation of $5.9 million for Q1 2026, up 2198.62% year-over-year from $257461.0 in Q1 2025, and up 39.15% quarter-over-quarter from $4.3 million in Q3 2025.
Capricor Therapeutics (CAPR) Share-based Compensation (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $5.9 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 2198.62% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $19.0 million (up 1161.58% YoY), while the FY2025 annual figure was $13.4 million, down 34.4% from the prior year.
- Share-based Compensation for Q1 2026 stood at $5.9 million, up from $4.3 million in the prior quarter.
- The five-year high for Share-based Compensation was $16.6 million in Q3 2024, with the low at -$7.5 million in Q4 2024.
- The 5-year median for Share-based Compensation is $1.8 million (2023), against an average of $2.9 million.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation plunged 501.22% in 2024, then soared 2198.62% in 2026.
- Capricor Therapeutics' Share-based Compensation stood at $1.1 million in 2022, then soared by 62.14% to $1.9 million in 2023, then slumped by 501.22% to -$7.5 million in 2024, then soared by 156.94% to $4.3 million in 2025, then soared by 39.15% to $5.9 million in 2026.
- Business Quant data shows CAPR's Share-based Compensation at $5.9 million in Q1 2026, $4.3 million in Q3 2025, and $8.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | 5.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.92 Mn |
| Mar 31, 2026 | 5.92 Mn |
| Sep 30, 2025 | 4.25 Mn |
| Sep 30, 2025 | 4.25 Mn |
| Jun 30, 2025 | 8.87 Mn |
| Jun 30, 2025 | 8.87 Mn |
| Mar 31, 2025 | 257,461.00 |
| Mar 31, 2025 | 257,461.00 |
| Dec 31, 2024 | -7.47 Mn |
| Dec 31, 2024 | -7.47 Mn |
| Sep 30, 2024 | 16.60 Mn |
| Sep 30, 2024 | 16.60 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Sep 30, 2023 | 1.72 Mn |
| Sep 30, 2023 | 1.72 Mn |